Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 84.93% | Cantor Fitzgerald | → $27 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 84.93% | Cantor Fitzgerald | $25 → $27 | Maintains | Overweight |
| 08/11/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 07/21/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 71.23% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 50.68% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 23.29% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 64.38% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 36.99% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 6.16% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 16.44% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 23.29% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -17.81% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -52.05% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -45.21% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -31.51% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -17.81% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -48.63% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -45.21% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -45.21% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月22日 | 84.93% | 康托·菲茨杰拉德 | →$27 | 重申 | 超重→超重 |
| 2023年08月11日 | 84.93% | 康托·菲茨杰拉德 | $25→$27 | 维护 | 超重 |
| 2023年08月11日 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 购买→购买 |
| 07/21/2023 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 购买→购买 |
| 2023年6月21日 | 64.38% | Truist证券 | $22→$24 | 维护 | 买 |
| 2023年6月21日 | 71.23% | 康托·菲茨杰拉德 | →$25 | 重申 | 超重→超重 |
| 06/20/2023 | 64.38% | Truist证券 | $22→$24 | 维护 | 买 |
| 2023年05月12日 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 购买→购买 |
| 03/20/2023 | 64.38% | HC Wainwright公司 | →$24 | 重申 | →购买 |
| 2023年1月19日 | 50.68% | Truist证券 | $18→$22 | 维护 | 买 |
| 2022年12月21日 | 23.29% | Truist证券 | $17→$18 | 维护 | 买 |
| 2022年12月21日 | 64.38% | HC Wainwright公司 | $18→$24 | 维护 | 买 |
| 12/20/2022 | 36.99% | 派珀·桑德勒 | $18→$20 | 维护 | 超重 |
| 2022年08月24日 | 6.16% | 罗斯资本 | $10→$15.5 | 评级下调 | 购买→中性 |
| 2022年08月11日 | 16.44% | Truist证券 | $12→$17 | 维护 | 买 |
| 2022年08月11日 | 23.29% | HC Wainwright公司 | $12→$18 | 维护 | 买 |
| 02/08/2022 | -17.81% | HC Wainwright公司 | $9→$12 | 维护 | 买 |
| 03/18/2021 | -52.05% | 罗斯资本 | $6.5→$7 | 维护 | 买 |
| 2020年08月12日 | -45.21% | Truist证券 | $10→$8 | 维护 | 买 |
| 2020/05/13 | -31.51% | SunTrust Robinson Humphrey | $11→$10 | 维护 | 买 |
| 02/14/2020 | -17.81% | 康托·菲茨杰拉德 | $11→$12 | 重申 | →超重 |
| 2018年12月13日 | -48.63% | 派珀·桑德勒 | $5→$7.5 | 维护 | 超重 |
| 2018年11月29日 | -45.21% | 康托·菲茨杰拉德 | →$8 | 重申 | →超重 |
| 2018年09月21日 | -45.21% | 康托·菲茨杰拉德 | →$8 | 开始承保 | →超重 |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
催化剂制药(CPRX)的目标价是多少？
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $27.00 expecting CPRX to rise to within 12 months (a possible 84.93% upside). 14 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月22日报道了催化剂制药公司(纳斯达克代码：CPRX)的最新目标价。这家分析公司将目标价定为27美元，预计CPRX将在12个月内升至(可能上涨84.93%)。过去一年，有14家分析公司公布了评级。
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
分析师对催化剂制药公司(CPRX)的最新评级是多少？
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by Cantor Fitzgerald, and Catalyst Pharmaceuticals reiterated their overweight rating.
分析师对Catalyst PharmPharmticals(纳斯达克代码：CPRX)的最新评级由坎托·菲茨杰拉德提供，Catalyst PharmPharmticals重申其增持评级。
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Catalyst PharmPharmticals(CPRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Catalyst PharmPharmticals的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Catalyst PharmPharmticals的上一次评级是在2023年8月22日提交的，因此您应该预计下一次评级将在2024年8月22日左右提供。
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
分析师对Catalyst PharmPharmticals(CPRX)的评级正确吗？
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $27.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $14.60, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Catalyst PharmPharmticals(CPRX)评级被重申，目标价在0.00美元至27.00美元之间。Catalyst PharmPharmticals(CPRX)目前的交易价格为14.60美元，在分析师的预测范围内。